Latest News
Kailera Therapeutics, Inc.
- Top Kailera Therapeutics (KLRA) Competitors 2026
- We Think Kailera Therapeutics (NASDAQ:KLRA) Can Afford To Drive Business Growth
- Companies Like Kailera Therapeutics (NASDAQ:KLRA) Are In A Position To Invest In Growth
- Kailera Therapeutics (KLRA): Post-180-Day Review: Heavyweight Backers, Lightweight Returns
- Jefferies reiterates Buy on Kailera stock, cites obesity pipeline By Investing.com
- Kailera Therapeutics (NasdaqGS:KLRA) Stock Forecast & Analyst Predictions
- TriGemX Bio Adds Kailera CFO Doug Pagán to Board
- Kailera, Hengrui’s GLP-1/GIP candidate delivers weight, menstrual benefits to women with PMOS
- Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting
- Kailera presents phase 1 data for ribupatide at EASD meeting By Investing.com
- Kailera Therapeutics (KLRA) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $KLRA
- Kailera Therapeutics Announces Completion of Enrollment in
Headlines from the last 30 days, linking to the original publishers. See all market news →